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Abstracts
The p75 neurotrophin receptor modulates differentiation and apoptosis in transit amplifying 
keratinocytes
Carlo Pincelli  University of Modena and Reggio Emilia, Italy
p75 neurotrophin receptor (p75NTR) belongs to the TNF-receptor superfamily and signals 
apoptosis in many cell settings. We evaluated the expression and function of p75NTR in human 
keratinocytes. p75NTR was confined to transit amplifying cells (TA). Moreover, calcium treatment 
of subconfluent keratinocytes induced the up-regulation of p75NTR concurrently with the 
expression of the differentiation markers. p75NTR retroviral infection of stem cells induced a more 
differentiated phenotype with the same features of TA cells. On the other hand, when p75NTR 
was silenced, calcium treatment failed to induce differentiation in subconfluent keratinocytes. 
Moreover, b-amyloid, a ligand for p75NTR, induced apoptosis in human keratinocytes only in 
p75NTR expressing keratinocytes, as shown by caspase-3 activation. Brain-derived neurotrophic 
factor (BDNF) or neurotrophin-4 (NT-4), which signal through p75NTR, determined a higher rate 
of apoptosis in HaCaT cells overexpressing p75NTR. On the other hand, NT-4 failed to induce 
cell death in p75NTRsiRNA transfected HaCaT cells. Because psoriasis is characterized by a 
dysregulation of epidermal homeostasis, namely alteration of differentiation and resistance to 
apoptosis, we evaluated the expression and function of p75NTR in this disease.  p75NTR was 
absent in lesional psoriatic skin and p75NTR levels were significantly lower in psoriatic than 
in normal TA keratinocytes. The rate of apoptosis in psoriatic TA cells was significantly lower, 
as compared to normal TA cells. p75NTR retroviral infection restored apoptosis in psoriatic 
keratinocytes. These results suggest that p75NTR has a dual role: it acts as a “switch on-off” in 
differentiation and/or as a pro-apoptotic receptor. Thus, p75NTR is essential  for maintaining 
epidermal homeostasis. 
Effect of chronic mild stress on skin and brain in the NC/Nga atopic-like mouse
Klas Nordlind, 1 S-B Lonne-Rahm, 1  H El-Nour,1  A Rasul, 1 L Grip, 1 M Holst, 2 B Johansson, 3 
L  Olson, 4 E Theodorsson 5  and RD Blakely 6 1 Department of Medicine, Solna, Dermatology 
and Venereology Unit, Karolinska Institutet, Stockholm Sweden, 2 Department of Woman and 
Child Health, Astrid Lindgren Children’s Hospital,  Solna,  Stockholm,  Sweden, 3  Departments 
of Molecular Medicine and Surgery, and 4 Neuroscience, Karolinska Institutet, Stockholm, 
Sweden, 5 IBK/Clinical Chemistry, University Hospital, Linköping, Sweden  and  6 Department 
of Pharmacology and Center for Molecular Neuroscience, Vanderbilt University Medical Center, 
Nashville, TN, USA 
Atopic eczema is often worsened by stress. We have studied the effect of chronic mild stress in the 
atopic-like NC/Nga mouse strain. The mice were subjected to chronic mild stress for 12 weeks and 
eczema was induced by applying a mite antigen (Dermatophagoides pteronyssinus) on the ears 
for the last 4 weeks. The mice were divided into stressed eczematous, non-stressed eczematous 
and stressed control groups. Serum corticosterone levels were determined at the endpoint of the 
experiment. The biopsies from skin and brain have been analyzed using immunohistochemistry 
and RT-PCR. The diameter of the ears was larger in the stressed eczematous group compared 
to the other groups. Moreover, the corticosterone levels were significantly lower in the stressed 
eczematous group. The neuromediators being studied are serotonin, its transporter protein, as 
well as its receptors, and the tachykinin substance P and its receptor neurokinin-1.
Regulatory mechanisms of epidermal innervations in atopic dermatitis 
Kenji Katamori (Chiba, Japan) Department of Dermatology, Juntendo University Urayasu 
Hospital, Chiba, Japan
Histamine, the best known pruritogen in human is also regarded as an experimental itch-
causing substance. Clinically, antihistamines, i.e., H1-receptor antagonist, are commonly used 
to treat all types of itch. However, antihistamines often lack efficacy in patients with chronic 
itch where other agonists may be involved including proteases, neuropeptides, cytokines, and 
opioids, and their cognate receptors, such as thermoreceptors, PAR-2, and opioid receptors. 
Such pruritogenic mediators and modulators released in the periphery may directly activate itch-
sensitive C-fibers by binding to specific receptors on the nerve terminals. Nerve fibers can also be 
activated by exogeneous mechanical, chemical, or biological stimuli, resulting in itch responses. 
Histological examination reveals that epidermal nerve densities are increased in patients with 
AD, suggesting that the higher density is partly responsible for the intense itching in the skin. 
Such hyperinnervation is probably caused by an imbalance of nerve elongation factors(e.g. 
nerve growth factor, amphiregulin, gelatinase) and nerve repulsion factors(e.g. semaphoring 
3A, anosmin-1), produced by keratinocytes. We recently demonstrated that neuronal matrix 
metalloproteinase-2 is involved in  penetration of sensory nerve fibers into basement membrane 
through modulation by axonal guidance molecules. Clinically, PUVA therapy reduce epidermal 
hyperinnervation in patients with AD by normalization of Sema3A and NGF expression in the 
epidermis, leading to decrease in scores on pruritus. Such anti-nerve growth effects were found 
in the dry skin of acetone-treated mice treated with narrowband UVB. Today I would like to talk 
about  the penetration mechanisms of nerve fibers into the epidermis in AD.
Pruritus – from bench to bedside and back
Martin Metz and Marcus Maurer
Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin 
Berlin, Germany
Pruritus is a major symptom of numerous skin and systemic diseases and causes a substantial 
burden on patients’ quality of life. The pathophysiology of itch is very diverse and it involves a 
complex network of cutaneous and neuronal cells which may vary substantially depending on 
the underlying cause of the pruritus. Experimental models of pruritus or pruritic diseases have 
enabled us in recent years to identify some new mediators and receptors which might be critically 
involved in chronic pruritus in some patients. Some of these findings have led to the development 
of novel pharmacological approaches aimed at the treatment of chronic pruritus. On the other 
hand, findings in patients and healthy subjects have led to hypotheses of specific itch-inducing 
mechanisms which have then been verified and characterized to some extent in experimental 
models. We and others have contributed to improve diagnosis and treatment of patients with 
chronic pruritus and to better understand the pathophysiological mechanisms underlying chronic 
pruritus. Here we will present the current thinking in the field, recent advances in basic science 
and clinical research, as well as novel approaches for the diagnosis and treatment of pruritus.
New Insights into the Brain-Skin Axis
Elyse Kleyn and Christopher C.M. Griffiths Dermatological Sciences, University of Manchester, 
Manchester, UK
Pruritus or itch is the most prevalent symptom of allergic and inflammatory skin disease.  Although 
it is known that itch induces activation a neural network in the brain, the temporal dynamics of 
the network as well as the pathophysiology and neurobiology are not well understood.  The study 
aimed to elucidate: (i) the temporal dynamics of the ‘itch matrix’ identified in earlier studies 
and; (ii) the relationship between central and subjective responses to itch. Using a novel time-
series analysis, we performed a double-blind, placebo-controlled, randomized, within-subject 
functional magnetic resonance imaging (fMRI) study of the cerebral processing of histamine-
induced itch in healthy volunteers (n=16) by tracking the 8 minute period following a single 
skin-prick.  Histamine-induced itch resulted in a significant positive signal in pre-hypothesised 
regions including the prefrontal motor cortex (Brodmann Area [BA] 6),  middle frontal gyri (BA 
10), postcentral gyrus (BA 3/4), somatosensory cortex (BA 43), inferior parietal cortex (BA 40) and 
posterior insula. A time-series analysis demonstrated progressive activation of distinct regions of 
prefrontal cortex in itch perception.  In contrast to other fMRI studies we observed multifocal 
negative signals. Further, our model showed that response to itch is maintained even as subjective 
perception starts to diminish.  An improved understanding of both activated and deactivated 
brain regions during the itch response may in the long-term facilitate development of more 
effective management strategies.
HPA-axis activity and stress reactivity in psoriasis
Andrea W.M. Evers Radboud University Medical Centre Nijmegen, The Netherlands
As the stress response involves activation of the HPA axis, which interacts with the immune 
system, stress-related factors might influence immune-mediated diseases, such as psoriasis, 
for example by affecting the secretion of proinflammatory cytokines. In this presentation, we 
give an short overview of several experimental and prospective studies about the possible 
relationship between psychophysiological stressfactors and the disease course of psoriasis. 
Preliminary evidence was found for a relationship between stressfactors and the course of 
psoriasis, for example by an altered cortisol response during exposure to stress. Increasing 
evidence further suggests that these factors seem to be particularly relevant during phases of 
high levels of daily stressors and for patients who report heightened stress levels during a longer 
period of time. Possible psychophysiological pathways and innovative tailored therapy options of 
psychopharmacological (pre)treatment combinations will be discussed. 
Evaluation of a psychological group intervention for patients with moderate and severe psoriasis
Lucia Tomas-Aragones and Servando E. Marron
Dermatology Department Alcañiz Hospital, Teruel and Psychology Department, University of 
Zaragoza. Aragon Health Sciences Institute (I+CS), Spain
Psoriasis is a chronic disease in which psychological distress is a common part of the illness 
experience. The burden of coping with a chronic disease can have a negative impact on the 
patient’s quality of life and psoriasis patients frequently report poor self-esteem and high levels of 
psychological stress. Psychoeducational groups focus on educating patients about their disorder 
and ways of coping. Current, up-to-date information is provided by the health professional 
and the participants share their concerns and strategies used to overcome difficulties related to 
their illness, in this case psoriasis. A total of 30 patients with moderate to severe psoriasis were 
randomly assigned to the control or intervention group. The 10 patients in the intervention group 
were offered 12 weekly sessions of 90 minutes of psychoeducational group therapy, consisting of 
health education, enhancement of problem-solving skills, stress management, and psychological 
support. The participants were assessed at baseline, before random assignment, and at the end of 
the 12 weeks. Inclusion criteria: Psoriasis Area Severity Index (PASI) ≥ 5;Dermatology Life Quality 
Index (DLQI) ≥ 6; Hospital Anxiety and Depression Scale (HADS) ≥ 11 in either the depression 
or the anxiety scale; signed consent form and willingness to participate. The preliminary results 
of the first intervention group and control group will be presented and discussed, as well as 
explaining the programme and the development of the group sessions. Finally, we will give 
an overview of the state of knowledge in psychoeducational group interventions for psoriasis 
patients and highlight the need to create evidence of its effectiveness.
Non-clinical influences on decision taking in dermatology clinics
Andrew Y Finlay, F M Hajjaj, M S Salek, M K A Basra
Schools of Medicine and Pharmacy, Cardiff University, Cardiff, Wales, UK
Every clinician knows that the process of taking clinical decisions is anything but straightforward. 
Although we accept that all decisions should be primarily be informed by scientific evidence, 
the reality of clinical medicine is extremely complex: the interweaving of evidence base with 
the particular circumstances and wishes of the individual patient along with the experience and 
wisdom of the clinician comprises the “art” of medicine.  Given the central place of decision taking 
in the raison d’être of the  medical profession it is extraordinary how little attention has been paid 
to this in the literature. It was clear to us from our clinical experience that in reality a very wide 
range of influences, such as the clinician’s perception of the patient’s impairment of quality of 
life, may play a role in clinical decision taking, including many influences that are usually denied 
or at least not acknowledged.  If these influences were better understood, it might be possible to 
train health care professionals to handle these influences more appropriately and hence improve 
the quality of clinical decision taking. The aim of our first study was to begin to understand this 
area by interviewing all dermatology clinicians in Wales, seeking their views on the role of non-
clinical influences on clinical decision making in dermatology outpatient clinics. Ethical approval 
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was obtained.  46 dermatology clinicians (94% of those in Wales) from 9 different hospitals in 
Wales, UK were interviewed. The opening question was “According to your experience, what are 
the non-clinical influences on your decision making in dermatology?”.  Interviews were recorded 
and analyzed. Non-clinical influences were either Patient-related, Physician-related or Practice-
related. Patient-related factors included adherence to medication (reported by all 46 clinicians), 
concerns and worries of patient (46), quality of life (46), expectations (45), family and friends 
attitudes (40), age (38), financial status (30), place of residence (29), ethnicity (28), attitude and 
behavior (24), sex (24), time commitments (22), choice (11), and education and intelligence 
(9).  Physician related influences included influence of colleagues (46), time constraints and 
work pressure (30) and influence of pharmaceutical companies (28).  Practice-related influences 
included cost of treatment to Health Service (27), working in private practice v. Health Service 
(8), availability of treatment service (7) and bureaucracy in prescribing certain medications (4). 
In a second study, 61 patient consultations were observed and patients interviewed after, to 
gain the patients’ perspectives on the role of non-clinical influences on the decisions that had 
been taken concerning themselves.  The insights of the patients were broadly similar to those 
revealed by dermatology clinicians in the previous study. It is often appropriate for clinicians 
to take into account non-clinical influences so that decisions are taken in the best interests of 
a specific patient; these are “good” influences.  However many influences were not necessarily 
appropriate: the ‘bad” influences. Such inappropriate non-clinical influences might include 
age, financial status, place of residence, ethnicity, attitude, sex, education, time constraints 
and influence of pharmaceutical companies. National guidelines seek to improve the quality of 
clinical decision taking by being evidence based.  However in reality guideline advice co-exists 
with often unrecognized non-clinical influences.  If clinicians had greater understanding of the 
processes involved in decision taking it might be possible to develop strategies to recognize and 
neutralize the inappropriate influences.  Greater understanding of this aspect of decision taking 
is necessary for evidence based decision taking to become a reality
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